Singer Michele L, Shin Mi-Kyung, Kim Lenise J, Freire Carla, Aung O, Pho Huy, East Joshua A, Sgambati Frank P, Latremoliere Alban, Pham Luu V, Polotsky Vsevolod Y
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
The Johns Hopkins Center for Interdisciplinary Sleep Research and Education (CISRE), Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Front Physiol. 2023 Dec 13;14:1320151. doi: 10.3389/fphys.2023.1320151. eCollection 2023.
Opioid-induced respiratory depression (OIRD) is the primary cause of death associated with opioids and individuals with obesity are particularly susceptible due to comorbid obstructive sleep apnea (OSA). Repeated exposure to opioids, as in the case of pain management, results in diminished therapeutic effect and/or the need for higher doses to maintain the same effect. With limited means to address the negative impact of repeated exposure it is critical to develop drugs that prevent deaths induced by opioids without reducing beneficial analgesia. We hypothesized that OIRD as a result of chronic opioid use can be attenuated by administration of IN leptin while also maintaining analgesia in both lean mice and mice with diet-induced obesity (DIO) of both sexes. To test this hypothesis, an opioid tolerance protocol was developed and a model of OIRD in mice chronically receiving morphine and tolerant to morphine analgesia was established. Subsequently, breathing was recorded by barometric plethysmography in four experimental groups: obese male, obese female, lean male, and lean female following acute administration of IN leptin. Respiratory data were complemented with measures of arterial blood gas. Operant behavioral assays were used to determine the impact of IN leptin on the analgesic efficacy of morphine. Acute administration of IN leptin significantly attenuated OIRD in DIO male mice decreasing the apnea index by 58.9% and apnea time by 60.1%. In lean mice leptin was ineffective. Blood gas measures confirmed the effectiveness of IN leptin for preventing respiratory acidosis in DIO male mice. However, IN leptin was not effective in lean mice of both sexes and appeared to exacerbate acid-base disturbances in DIO female mice. Additionally, morphine caused a complete loss of temperature aversion which was not reduced by intranasal leptin indicating IN leptin does not decrease morphine analgesia. IN leptin effectively treated OIRD in morphine-tolerant DIO male mice without impacting analgesia. In contrast, IN leptin had no effect in lean mice of either sex or DIO female mice. The arterial blood gas data were consistent with ventilatory findings showing that IN leptin reversed morphine-induced respiratory acidosis only in DIO male mice but not in other mouse groups. Finally, a hypercapnic sensitivity study revealed that IN leptin rescued minute ventilation under hypercapnic conditions only in DIO male mice, which suggests that differential responses to IN leptin are attributable to different leptin sensitivities depending on sex and the obesity status.
阿片类药物引起的呼吸抑制(OIRD)是与阿片类药物相关的主要死亡原因,肥胖个体由于合并阻塞性睡眠呼吸暂停(OSA)而特别容易受到影响。反复接触阿片类药物,如在疼痛管理中,会导致治疗效果降低和/或需要更高剂量来维持相同效果。由于应对反复接触的负面影响的手段有限,开发既能预防阿片类药物引起的死亡又不降低有益镇痛效果的药物至关重要。我们假设,通过鼻内给予瘦素,可以减轻慢性使用阿片类药物导致的OIRD,同时在雄性和雌性的瘦小鼠以及饮食诱导肥胖(DIO)小鼠中维持镇痛效果。为了验证这一假设,我们制定了阿片类药物耐受方案,并建立了长期接受吗啡且对吗啡镇痛产生耐受的小鼠OIRD模型。随后,通过气压体积描记法记录了四个实验组(肥胖雄性、肥胖雌性、瘦雄性和瘦雌性)在急性鼻内给予瘦素后的呼吸情况。呼吸数据通过动脉血气测量进行补充。采用操作性行为测定法来确定鼻内给予瘦素对吗啡镇痛效果的影响。急性鼻内给予瘦素可显著减轻DIO雄性小鼠的OIRD,呼吸暂停指数降低58.9%,呼吸暂停时间降低60.1%。在瘦小鼠中,瘦素无效。血气测量证实了鼻内给予瘦素对预防DIO雄性小鼠呼吸性酸中毒的有效性。然而,鼻内给予瘦素对两性瘦小鼠均无效,且似乎会加重DIO雌性小鼠的酸碱紊乱。此外,吗啡导致温度厌恶完全丧失,鼻内瘦素并未使其减轻,这表明鼻内瘦素不会降低吗啡的镇痛效果。鼻内给予瘦素可有效治疗吗啡耐受的DIO雄性小鼠的OIRD,且不影响镇痛效果。相比之下,鼻内给予瘦素对两性瘦小鼠或DIO雌性小鼠均无作用。动脉血气数据与通气结果一致,表明鼻内给予瘦素仅在DIO雄性小鼠中逆转了吗啡诱导的呼吸性酸中毒,而在其他小鼠组中则没有。最后,一项高碳酸血症敏感性研究表明,鼻内给予瘦素仅在DIO雄性小鼠的高碳酸血症条件下挽救了分钟通气量,这表明对鼻内给予瘦素的不同反应归因于取决于性别和肥胖状态的不同瘦素敏感性。